Bayer HealthCare Ranks Top In China
This article was originally published in PharmAsia News
Executive Summary
Bayer HealthCare may rank 10 on the global pharmaceutical market, but according to research firm IMS's Q1 2008 figures, the firm's prescription drug revenue was top in China. The result was corroborated by China's R&D-based Pharmaceutical Association Committee's Q1 figures. The acquisition of Topsun Science and Technology's OTC business has raised Bayer's profile in the country and will double its OTC sales. Bayer China discloses that Bayer HealthCare revenue in the country is expected to grow 40 percent this year to over RMB 4.5 billion ($658.8 million). However, there are soft spots such as the gynecology sector, which fails to capitalize on the firm's global strength to translate into significant sales in China. Also, investment in local community health services will need time for the results to be seen. (Click here for more - Chinese Language)